UNSPSC 51331705: Piracetam

This classification denotes a neuroprotective agent with the molecular formula C6H10N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZH516LNZ10, chemically known as 1-pyrrolidineacetamide, 2-oxo- but generally known as piracetam, which bears US NIH Compound Identifier 4843. European Medicines Agency schedules Piracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09892MIG.

UNSPSC 51331705 Piracetam (Commodity) does not align with the recent state and local contract opportunities posted under this code. The source records show Seminole County, Florida procuring naloxone and drug deactivation systems; Texas Health and Human Services Commission issuing a Request for Information on direct-to-manufacturer prescription programs; and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) soliciting generic multi-source pharmaceuticals and over-the-counter products — none of which are piracetam or piracetam-specific procurements. Piracetam is a nootropic pharmaceutical with limited clinical use in the United States; the recent opportunities tagged under this code reflect broader pharmaceutical procurement, controlled-substance distribution, and pharmacy benefit management instead. State and local issuers posting under this code appear to span county health departments, state health and human services agencies, and cooperative purchasing alliances supporting multi-state procurement.

Recent activity shows geographic spread across Florida, Texas, and Minnesota. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. The Texas HHS Commission's RFI (HHS0017013, April 3, 2026) gathered vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP's RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026. This code shows limited recent piracetam-specific activity; procurement under it appears driven by broader pharmaceutical supply and pharmacy benefit consolidation rather than nootropic agents.